Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
37 hedge funds and large institutions have $118M invested in Sinovac Biotech, Ltd in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
23% more call options, than puts
Call options by funds: $266K | Put options by funds: $217K
9% more capital invested
Capital invested by funds: $108M → $118M (+$9.47M)
6% more funds holding
Funds holding: 35 → 37 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GP
GLG Partners
London,
United Kingdom
|
+$916K |
| 2 |
Renaissance Technologies
New York
|
+$739K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$432K |
| 4 |
Walleye Trading
New York
|
+$264K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$9.42M |
| 2 |
Two Sigma Investments
New York
|
-$708K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$90.6K |
| 4 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$83K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$80K |
SVA Hedge Fund Activity: Q2 2017 in Review
37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2017, worth a combined $118M — up 8.7% from $108M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SVA positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was GLG Partners, adding an estimated $916K. The largest seller was Morgan Stanley, cutting an estimated $9.42M.
- 37 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2017, up from 35 in Q1 2017.
- Funds reported $118M of Sinovac Biotech, Ltd stock for Q2 2017, up 8.7% quarter-over-quarter.
- 8 funds opened new Sinovac Biotech, Ltd positions in Q2 2017 and 6 closed out, a net change of +2 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2017 was GLG Partners, an estimated $916K added.
- The largest Sinovac Biotech, Ltd seller in Q2 2017 was Morgan Stanley, an estimated $9.42M sold.
Based on aggregated 13F filings for Q2 2017.